Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?

被引:13
作者
Bastida, Carla [1 ]
Antonia Also, Maria [2 ]
Manuel Pericas, Juan [2 ]
Letang, Emili [3 ,4 ]
Tuset, Montse [1 ]
Maria Miro, Josep [2 ]
机构
[1] Hosp Clin Barcelona, Serv Farm, Barcelona, Spain
[2] Hosp Clin Barcelona, Inst Clin Med & Dermatol, Serv Enfermedades Infecciosas, Barcelona, Spain
[3] Swiss Trop & Publ Hlth Inst Swiss TPH, Basel, Switzerland
[4] Univ Barcelona, Hosp Clin, CRESIB, Barcelona, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2014年 / 32卷 / 09期
关键词
Drug-drug interactions; Rhabdomyolysis; Renal failure; Hepatotoxicity; Hydroxymethylglutaryl-CoA reductase inhibitors; Human immunodeficiency virus; Antiretroviral drugs; Ritonavir; Statins; Simvastatin; INHIBITORS;
D O I
10.1016/j.eimc.2014.03.014
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Drugs like statins may induce rhabdomyolysis. Simvastatin and lovastatin have a high hepatic metabolism and their potential toxicity could be increased by interactions with other drugs that reduce their metabolism. Patients and methods: A case-report is presented of an HIV-infected patient treated with antiretroviral drugs who developed a rhabdomyolysis-induced renal failure and liver toxicity when simvastatin was substituted for atorvastatin. A literature review is also presented. Results: The patient required hospital admission and showed a favorable response after hydration and urine alkalinization. There were 4 additional cases published of which there was one death. Conclusions: Drug-drug interactions can increase the risk of statin induced rhabdomyolysis. In order to evaluate them properly, physicians at all levels of clinical care should be aware of all drugs prescribed to their patients and the contraindicated combinations. (C) 2014 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.
引用
收藏
页码:579 / 582
页数:4
相关论文
共 12 条
  • [1] [Anonymous], 2014, ZOC SIMV FICH TECN
  • [2] [Anonymous], PROT UT EST
  • [3] Safety of statins - Focus on clinical pharmacokinetics and drug interactions
    Bellosta, S
    Paoletti, R
    Corsini, A
    [J]. CIRCULATION, 2004, 109 (23) : 50 - 57
  • [4] Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Chauvin, Benoit
    Drouot, Sylvain
    Barrail-Tran, Aurelie
    Taburet, Anne-Marie
    [J]. CLINICAL PHARMACOKINETICS, 2013, 52 (10) : 815 - 831
  • [5] Rhabdomyolysis due to probable interaction between simvastatin and ritonavir
    Cheng, CH
    Miller, C
    Lowe, C
    Pearson, VE
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (08) : 728 - 730
  • [6] FDA MedWatch, 2012, FDA DRUG SAF COMM IN
  • [7] Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death
    Hare, CB
    Vu, MP
    Grunfeld, C
    Lampiris, HW
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) : E111 - E112
  • [8] Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
    Jacobson, TA
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (09) : 1140 - 1146
  • [9] Khan FY, 2009, NETH J MED, V67, P272
  • [10] MARTIN CM, 2000, 40 INT C ANT AG CHEM